SEC Form 4 · accession 0001140361-16-088121
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — President, Worldwide R&D
Period of report
Nov 25, 2016
Accepted (ET)
Nov 29, 2016 · 8:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 25, 2016 | M | 15,000 | $26.49 | A | 128,878 | D | |
| Common StockF1,F2 | Nov 25, 2016 | S | 15,000 | $87.3992 | D | 113,878 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F3 | $26.49 | Nov 25, 2016 | M | 15,000 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 15,000 | 35,225 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 12, 2016.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $86.67 to $88.06. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.